Physician profile
Robert P Hogan
NPI 1396708632
$1,198.87
in general payments reported to CMS, 2019-2025
25 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $63.77 · 2021: $38.01 · 2022: $74.13 · 2023: $42.06 · 2024: $119 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.82 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Novo Nordisk INC | $115.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $104.21 | 2019-2021 | |
| Pfizer INC. | $99.13 | 2020-2025 | |
| Glaxosmithkline, LLC. | $97.13 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $68.20 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $58.20 | 2019-2020 | |
| Exact Sciences Corporation | $57.92 | 2025 | Cologuard Collection Kit |
| Indivior INC. | $56.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $38.92 | 2025 | |
| Sanofi Pasteur INC. | $29.84 | 2019-2021 | |
| Dexcom, INC. | $21.71 | 2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $18.33 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.85 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $14.74 | 2025 | Lumryz |
| Xeris Pharmaceuticals, INC. | $13.94 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.70 | 2025 | Voquezna |
| Kaleo, INC. | $13.28 | 2019 | |
| Dynavax Technologies Corporation | $12.27 | 2023 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $12.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.64 | 2019 | |
| Allergan, INC. | $11.32 | 2019 | |
| Circassia INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.